MET and medullary thyroid gland carcinoma: Strikingly, we observed an inverse trend of response to cell treatment with the multi-kinase inhibitor cabozantinib, approved for the therapy of advanced medullary thyroid cancer and hepatocellular and renal cell carcinoma [37], and the experimental c-MET inhibitor tivantinib comparing resistant and parental cells.